| Xu, Ruihua |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
FRUTIGA, NCT03223376: A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer |
|
|
| Active, not recruiting | 3 | 703 | RoW | fruquintinib +paclitaxel, HMPL-013+paclitaxel, fruquintinib placebo + paclitaxel, HMPL-013 placebo+paclitaxel | Hutchison Medipharma Limited, Sun Yat-sen University | Advanced Gastric Cancer | 09/22 | 11/22 | | |
|
|
|
|
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NCT06296706: A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer |
|
|
| Not yet recruiting | 3 | 630 | NA | Docetaxel for injection (Albumin-bound), HB1801, Taxotere (docetaxel), Taxotere | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Gastric Cancer | 06/26 | 06/27 | | |
NCT06022861: A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 510 | RoW | LY01015, Fluorouracil, Cisplatin, Opdivo® | Shandong Boan Biotechnology Co., Ltd | Esophageal Squamous Cell Carcinoma | 06/25 | 12/26 | | |
CIBI310L301, NCT05890742: A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer |
|
|
| Recruiting | 3 | 360 | RoW | Sintilimab, IBI310&Sintilimab, Radical surgery | Innovent Biologics (Suzhou) Co. Ltd. | MSI-H | 04/28 | 07/28 | | |
NCT04856787: A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC |
|
|
| Recruiting | 2/3 | 439 | RoW | SHR-1701、 BP102 、XELOX, placebo、 BP102、 XELOX | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Metastatic Colorectal Cancer (mCRC) | 11/22 | 11/24 | | |
ASTRUM-015, NCT04547166: A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) |
|
|
| Recruiting | 2/3 | 568 | Japan, RoW | HLX10, serplulimab, HLX04、, Bevacizumab | Shanghai Henlius Biotech | Metastatic Colorectal Cancer | 09/25 | 12/26 | | |
NCT05945901: A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer |
|
|
| Recruiting | 2/3 | 606 | RoW | HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab | Jiangsu HengRui Medicine Co., Ltd. | Colorectal Cancer | 12/25 | 12/26 | | |
NCT05705635: A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer |
|
|
| Recruiting | 2 | 100 | RoW | Docetaxel for injection (Albumin-bound), Taxotere | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Gastric Adenocarcinoma, Adenocarcinoma of Gastroesophageal Junction | 05/23 | 12/24 | | |
NCT05117658: Study of HA121-28 in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 83 | RoW | HA121-28 tablet | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NSCLC | 10/23 | 10/23 | | |
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 238 | RoW | MRG003, Capecitabine tablets, Docetaxel injection | Shanghai Miracogen Inc. | Recurrent or Metastatic Nasopharyngeal Carcinoma | 10/24 | 02/25 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
NCT04856774: Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors |
|
|
| Completed | 1/2 | 81 | RoW | SHR-1701；BP102 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 03/24 | 03/24 | | |
NCT04685226: A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 310 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumors | 06/25 | 02/28 | | |
NCT04284488: Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors |
|
|
| Recruiting | 1/2 | 104 | RoW | APG-1387 for Injection, Toripalimab, JS001 | Ascentage Pharma Group Inc. | Advanced Solid Tumor | 04/24 | 04/24 | | |
NCT06376136: A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors |
|
|
| Recruiting | 1/2 | 108 | RoW | BAT8010 for Injection, BAT1006 for Injection | Bio-Thera Solutions | Advanced Solid Tumors | 12/24 | 12/26 | | |
NCT05745623: A Phase 2 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors |
|
|
| Recruiting | 1/2 | 55 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion | 06/24 | 12/26 | | |
NCT05688605: A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 18 | RoW | MRG003+HX008 | Shanghai Miracogen Inc. | Advanced Solid Tumors | 05/25 | 07/25 | | |
| Active, not recruiting | 1/2 | 49 | Europe, Japan, US, RoW | TAK-981, Pembrolizumab | Takeda, Takeda Development Center Americas, Inc. | Advanced or Metastatic Solid Tumors | 11/25 | 11/25 | | |
NCT05877651: MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy. |
|
|
| Completed | 1 | 22 | RoW | MASCT-I injection | SYZ Cell Therapy Co.. | Solid Tumors | 10/21 | 10/21 | | |
NCT05015309: A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor |
|
|
| Not yet recruiting | 1 | 40 | RoW | SH3765 tablet | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Advanced Malignant Tumor | 03/23 | 09/24 | | |
NCT05380882: Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers |
|
|
| Recruiting | 1 | 60 | RoW | TQB2930 injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Cancers | 04/23 | 12/23 | | |
NCT03544905: Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33 |
|
|
| Recruiting | 1 | 100 | RoW | CYH33 for tablet | Haihe Biopharma Co., Ltd. | Advanced Solid Tumors | 06/23 | 03/24 | | |
MASCT-I, NCT03034304: A Phase I Clinical Study for Evaluating the Safety and Efficacy of in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 193 | RoW | MASCT-I, Ifosfamide, PD1 antibody, Adriamycin, Gemcitabine, Cisplatin, Carboplatin | SYZ Cell Therapy Co.. | Advanced Solid Tumors | 07/23 | 07/23 | | |
NCT04877717: A Study of SHR-A1904 in Patients With Advanced Solid Cancer |
|
|
| Recruiting | 1 | 94 | RoW | SHR-A1904 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Cancer | 10/23 | 01/24 | | |
NCT06166472: A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor |
|
|
| Not yet recruiting | 1 | 72 | RoW | AK132 | Akeso | Advanced Malignant Solid Tumor | 04/26 | 07/26 | | |
| Recruiting | 1 | 270 | RoW | NBL-028 | NovaRock Biotherapeutics, Ltd | Advanced Solid Tumor | 01/27 | 01/27 | | |
NCT05735496: Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers |
|
|
| Not yet recruiting | 1 | 71 | RoW | TQB2102 injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Cancer | 04/24 | 10/24 | | |
NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
| Recruiting | 1 | 924 | RoW | SHR-A1904; Adebrelimab, SHR-A1904; CAPOX; Adebrelimab | Shanghai Hengrui Pharmaceutical Co., Ltd. | Cldn18.2-positive Advanced Solid Tumor | 12/27 | 12/28 | | |
NCT05385692: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-M02D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Digestive Tract Tumors, Solid Tumor | 06/24 | 06/24 | | |
NCT05690581: Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies |
|
|
| Recruiting | 1 | 146 | RoW | CM369 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumors and Hematologic Malignancies | 06/24 | 04/25 | | |
NCT05867303: A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 48 | RoW | RC198 Injection | RemeGen Co., Ltd. | Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma | 06/24 | 09/24 | | |
| Recruiting | 1 | 100 | RoW | HQP1351 | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult | 12/24 | 12/26 | | |
NCT05979155: A Study of NWY001 in Subjects With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 196 | RoW | NWY001 | Chipscreen Biosciences, Ltd. | Advanced Solid Tumor | 01/26 | 05/28 | | |
NCT06094556: An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 240 | RoW | SHR-1826 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 06/27 | 07/27 | | |
| Xu, Rui-hua |
NCT05737563: PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC |
|
|
| Recruiting | 3 | 380 | RoW | PD-1 Inhibitors, Irinotecan, Capecitabine tablets | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd., Jiangsu HengRui Medicine Co., Ltd. | Esophageal Squamous Cell Carcinoma Abdominal Stage 0 | 02/26 | 02/26 | | |
NCT06396637: PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC |
|
|
| Recruiting | 2 | 20 | RoW | Sapropterin Dihydrochloride, PD-1 Antibody | Sun Yat-sen University, Innovent Biologics (Suzhou) Co. Ltd. | Pancreatic Adenocarcinoma Metastatic | 04/25 | 04/25 | | |
NCT05173246: JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma |
|
|
| Recruiting | 2 | 43 | RoW | JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection, nab-paclitaxel, Paclitaxel for injection (Albumin Bound), Cisplatin, Cisplatin for injection, Carboplatin, Carboplatin for injection | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd., CSPC Ouyi Pharmaceutical Co., Ltd. | Esophageal Small Cell Carcinoma | 11/24 | 11/25 | | |
| Wang, Feng |
NCT06301854: Long-term Safety of TPN171H Tablet in Erectile Dysfunction. |
|
|
| Recruiting | 3 | 400 | RoW | TPN171H, Simmerafil | Vigonvita Life Sciences | Erectile Dysfunction | 04/25 | 04/25 | | |
NCT05737563: PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC |
|
|
| Recruiting | 3 | 380 | RoW | PD-1 Inhibitors, Irinotecan, Capecitabine tablets | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd., Jiangsu HengRui Medicine Co., Ltd. | Esophageal Squamous Cell Carcinoma Abdominal Stage 0 | 02/26 | 02/26 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
SHR-1210-02, NCT03917966: The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC |
|
|
| Recruiting | 2 | 80 | RoW | SHR-1210+docetaxel+nedaplatin, SHR-1210+Apatinib | The First Affiliated Hospital of Zhengzhou University, Jiangsu HengRui Medicine Co., Ltd. | Locally Advanced Esophageal Squamous Cell Carcinoma | 10/23 | 10/24 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT05441046: Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 120 | RoW | Genakumab, Tislelizumab | GeneScience Pharmaceuticals Co., Ltd. | Malignant Solid Tumors | 06/24 | 03/25 | | |
| Recruiting | N/A | 349 | RoW | CAPEOX adjuvant therapy, deferred CAPEOX adjuvant therapy, mFOLFOXIRI intensive adjuvant therapy | Sun Yat-sen University, Guangzhou Burning Rock Dx Co., Ltd. | Colorectal Cancer | 07/28 | 07/28 | | |
NCT05593224: The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Intracranial Atherosclerotic Stenosis |
|
|
| Not yet recruiting | N/A | 156 | RoW | Intracranial Stent (Tonbridge) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Intracranial Atherosclerosis | 11/23 | 05/25 | | |
NCT05415995: A Trail of Drug-coated Balloon Treating Below The Knee Arterial Diseases |
|
|
| Recruiting | N/A | 202 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Artery Disease | 12/23 | 12/24 | | |
NCT05757505: The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis |
|
|
| Not yet recruiting | N/A | 200 | RoW | Intracranial Stent (Tonbridge), Wingspan Stent System (Stryker Neurovascular) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Intracranial Atherosclerosis | 12/23 | 12/25 | | |
NCT05719688: Evaluate the Safety and Efficacy of Thrombectomy System in the Intravascular Treatment of Acute Ischemic Stroke |
|
|
| Recruiting | N/A | 200 | RoW | Mechanical thrombectomy | Suzhou Hengruihongyuan Medical Technology Co. LTD | Acute Ischemic Stroke | 12/23 | 12/24 | | |
GENIUS, NCT04849325: IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease |
|
|
| Recruiting | N/A | 120 | RoW | Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titanâ„¢), Percutaneous Transluminal Angioplasty (PTA) Device | Biotyx Medical (Shenzhen) Co., Ltd. | Critical Limb Ischemia (CLI) | 04/24 | 10/24 | | |
| Not yet recruiting | N/A | 200 | RoW | antibiotic-impregnated catheter | Integra LifeSciences Corporation | Hydrocephalus | 07/26 | 12/26 | | |
